The Drama Continues At Amylin Pharmaceuticals: Takeover Still Likely

Fri, 04/27/2012 - 04:15 EDT - Seeking Alpha

By Helix Investment Management:Every so often, a company gets caught up in what seems like a soap opera of drama and intrigue. Analysts and investors try endlessly to decipher what is going on as management stays silent. Currently, Amylin Pharmaceuticals (AMLN) is caught up in just such a drama. However, even as management stays silent for the most part, there are several clues that can reveal what is happening at Amylin.Since Bloomberg reported on March 28 that Amylin had rejected a takeover offer from Bristol-Myers Squibb (BMY) that valued the company at $22 per share, the company has been he subject of much speculation. Management has largely stayed silent, while Carl Icahn has been anything but silent. Icahn had sued Amylin, arguing for an extension to nominate directors to stand for election at the company's annual meeting. And in a letter sent to Amylin's board of directors, Icahn stated outright that heComplete Story »

Original article
Login or register to post comments

Amylin Pharmaceuticals Takeover Offer: How To Proceed From Here
By Helix Investment Management:In the biotechnology sector, takeovers are more frequent than in any other sector, due to the desire of large pharmaceutical companies to augment their drug portfolios with new medicines. As of Wednesday, March 28, there is a potential new company facing a takeover: Amylin Pharmaceuticals (AMLN).
The Race For Amylin Kicks Into High-Gear
By Thomas Kee: It is becoming more and more likely that the biopharmaceutical company Amylin Pharmaceuticals (AMLN) will soon be acquired. Shares of Amylin jumped 8.4% on Friday to push the stock to its highest level since 2008.
Bristol-Myers Squibb: Amylin Acquisition Will Pay Off In The Long-Term
By Cris Frangold: Numerous possibilities of acquisitions and partnerships are flooding the pharmaceutical sector.
Bristol-Myers Squibb: Don't Miss This Attractive Entry Point
By Vatalyst: Big Pharma has been in the news a lot lately - from the Supreme Court decision on "Obamacare" to the troubling fine that GlaxoSmithKline (GSK) faces - but for Bristol-Myers (BMY) Squibb, the news has been mostly positive (and with GlaxoSmithKline pleading guilty to introducing two misbranded drugs to interstat
Bristol-Myers Squibb: The Acquisition Of Amylin Is A Modest Positive
By Smith On Stocks:I prefer growth through internal product development over growth through acquisition. It is the product pipeline that drives my buy recommendation on Bristol-Myers Squibb Company (BMY).
Bristol-Myers Buys Amylin, Glaxo Eyes Human Genome, Obagi Buy-Out Rumors, Ampio Surges
By Scott Matusow:Bristol-Myers Squibb (BMY) has agreed to pay $5.3 billion to acquire Amylin Pharmaceuticals (AMLN), a maker of diabetes therapies, as it seeks to suppleme
Amylin Pharmaceuticals: Enter Carl Icahn And The Proxy Battle
By Helix Investment Management:Fresh off his victory over the board of directors of CVR Energy (CVI) in his battle to take control of the company, Carl Icahn is now turning his sights to Amylin Pharmaceuticals (AMLN).
Amylin Pharmaceuticals: Unless A Bidding War Is Ignited, Tender
By Robert Broens: Shareholders of Amylin Pharmaceuticals (AMLN) are the absolute winners on Wall Street today after the company reportedly rejected an unsolicited $3.5 billion offer last month from British pharmaceutical giant Bristol-Myers Squibb. In a reaction to the news, shares ended the day 54% higher to close at $23.44
Amylin Bows Out Gracefully
By Stephen Simpson:The long drama around the Amylin Pharmaceuticals (AMLN) looks like it has reached its end - Bristol-Myers Squibb (BMY) announced the acquisition of Amylin late Friday night in a deal that will pay Amylin shareholders $31 per share in cash.
Amylin rejected $3.5 billion Bristol offer: Bloomberg

Main menu

Secondary menu

The Drama Continues At Amylin Pharmaceuticals: Takeover Still Likely

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu